2024
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults
Rostad C, Atmar R, Walter E, Frey S, Meier J, Sherman A, Lai L, Tsong R, Kao C, Raabe V, Sahly H, Keitel W, Whitaker J, Smith M, Schmader K, Swamy G, Abate G, Winokur P, Buchanan W, Cross K, Wegel A, Xu Y, Yildirim I, Kamidani S, Rouphael N, Roberts P, Mulligan M, Anderson E. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clinical Infectious Diseases 2024, 78: 1757-1768. PMID: 38537255, PMCID: PMC11175706, DOI: 10.1093/cid/ciae173.Peer-Reviewed Original ResearchInactivated influenza vaccinePhase 2 clinical trialInfluenza virus vaccineAS03-adjuvantedHemagglutination inhibitionVirus vaccineBoosting intervalsPrime-boost vaccination schedulesHuman influenza A(H7N9Injection site reactogenicityHeterologous prime-boost strategyAntigenically distinct lineagesPrime-boost strategyPrime-boost intervalVaccine groupHealthy US adultsNeutralizing antibody titersPeak antibody responseSystemic reactogenicityInfluenza vaccinePartially-blindedSecond dosePrime-boostReactogenicityImmune responseA Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults
Kao C, Rostad C, Nolan L, Peters E, Kleinhenz J, Sherman J, Tippett A, Shih J, Yildirim I, Agbakoba V, Beresnev T, Ballou C, Kamidani S, Karmali V, Natrajan M, Scherer E, Rouphael N, Anderson E. A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults. The Journal Of Infectious Diseases 2024, jiae148. PMID: 38536442, DOI: 10.1093/infdis/jiae148.Peer-Reviewed Original ResearchHealthy US adultsDouble-blindThird dosePlacebo-Controlled Clinical TrialSystemic reactionsHepatitis E virus vaccineUS adultsHepatitis E vaccinePlacebo groupPlacebo-controlledAdverse eventsE vaccineSecond doseClinical trialsDay 1Immune responseDosePhase 1ImmunogenicityMonthsSafety studiesVaccineInfant mortalityTrialsAdults
2018
2280. Antibiotic Exposure Does Not Impact Serological Responses to Rotavirus Vaccination
Anderson E, Lopman B, Yi J, Yildirim I, Creech C, El-Khorazaty J, Shane A, Edwards K. 2280. Antibiotic Exposure Does Not Impact Serological Responses to Rotavirus Vaccination. Open Forum Infectious Diseases 2018, 5: s675-s676. PMCID: PMC6255677, DOI: 10.1093/ofid/ofy210.1933.Peer-Reviewed Original ResearchGeometric mean titersAntibiotic exposureLogistic regression modelsRV vaccinesMultivariable logistic regression modelConcomitant antibiotic useRV immunizationLast doseVaccine doseVaccine groupImmunized childrenPrimary outcomeRotavirus immunizationAntibiotic administrationMean titersRegression modelsVaccine dosesSerological responseTreatment allocationAntibiotic useInclusion criteriaVaccine studiesImmune responseTreatment groupsSeroresponses